Shah Capital Nominates Two Independent Director Candidates For Novavax
Shah Capital Nominates Two Independent Director Candidates For Novavax
Shah Capital, which owns approximately 6.7% of the outstanding common stock of Novavax, recommends the appointment to Novavax board of two new independent directors: Suresh Katta and Venkat Peri. Shah Capital which owns 6.7% of Novavax, in a letter to the board says that the low share price reflects the board and management's failure to capitalize on Novavax's many significant competitive advantages and TAM opportunities. The letter highlights that the underperformance is self-inflicted and is the result of reactive leadership and outdated and old-fashioned marketing.
擁有Novavax已發行普通股約6.7％的Shah Capital建議在Novavax董事會任命兩名新的獨立董事：蘇雷什·卡塔和文卡特·佩裏。擁有Novavax6.7％股份的Shah Capital在給董事會的一封信中表示，低股價反映了董事會和管理層未能利用Novavax的許多重大競爭優勢和TAM機會。這封信強調，表現不佳是自己造成的，是被動領導和過時和過時的過時營銷的結果。
譯文內容由第三人軟體翻譯。